Radioactive therapy targets rare tumors in new trial

NCT ID NCT03206060

Recruiting now Disease control Sponsor: National Cancer Institute (NCI) Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tests a radioactive drug called Lu-177-DOTATATE in 130 adults with rare adrenal or neck tumors that cannot be surgically removed. The drug is given four times over about 8 months, and researchers track how long the cancer stays under control. The goal is to see if the treatment is safe and can delay tumor growth.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Lu-177-DOTATATE (a radioactive drug that targets tumor cells)
What this could lead to: If successful, this could provide a new treatment option for people with rare, inoperable adrenal or neck tumors, potentially slowing cancer growth.
What could go wrong: This is a mid-stage trial with only 130 participants, so results may not apply to everyone. The drug uses radiation, which can cause side effects like fatigue or blood cell changes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NEUROENDOCRINE NEOPLASMS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hypertensive disorder neuroendocrine neoplasm paraganglioma pheochromocytoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NEUROENDOCRINE NEOPLASMS NEUROENDOCRINE TUMORS PARAGANGLIOMA PHEOCHROMOCYTOMA

Contacts and locations

Locations

National Institutes of Health Clinical Center
RECRUITING

Bethesda, Maryland, 20892, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.